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Abstract 
Polycystic ovary syndrome (PCOS) is often associated with 
obesity, insulin resistance, irregular menstrual periods and 
pelvic pain. Treatment involves hormonal methods for 
regulation of menstrual cycle, lifestyle changes and 
metformin for improving insulin resistance and weight. The 
aim of our study was to compare changes in body mass 
index (BMI) of adolescent female with PCOS treated with 
metformin as compared to lifestyle modification only. 
Participants: Adolescent and young adult females aged I 0-
25 years diagnosed with PCOS seen for at least two visits 
for at least one year on the same treatment. Based on 
treatment plan, participants were categorized as metformin 
(metformin + lifestyle changes; metformin + oral 
contraceptive pills+ lifestyle changes) versus control group 
( oral contraceptive pills + lifestyle changes; lifestyle 
changes only). Results: Of the 464 charts reviewed, 134 
participants met the inclusion criteria. The average time 
period between the initial and follow up visit on same 
treatment plan was two years (Range 1-8 years).The 
average age of patients at baseline (initial visit) and follow 
up was 15.3 and 17.7 years, respectively. The majority of 
participants were overweight or obese at baseline and 
follow up. There was not a significant difference between 
the metformin and control group in the number of patients 
who stayed in the same BMI category, went up in a BMI 
category, or went dowo in a BMI category from baseline to 
follow up (x" - 1.93, p - 0.38). Conclusion: Treatment 
with metformin did not relate to changes in BMI 
classification over a year or more. 
Keywords: Obesity, PCOS, metformin, adolescent female, 
BMI 
Introduction 
Polycystic ovary syndrome (PCOS) is a complex 
endocrine disorder among reproductive age women. It 
is characterized b y  chronic anovulation leading to 
menstrual irregularities, pelvic pain and hy p er-
androgenism manifested as hirsutism, acne, and 
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alopecia along with elevated serum androgen levels 
(1 ). PCOS is diagnosed using various criteria 
commonly known as NIH, Rotterdam and Androgen 
Excess society. In 1990, the National Institutes o f  
Health (NIH) held a conference on PCOS to create 
both a working definition of  the disorder and 
diagnostic criteria. The outcome of  this conference, 
the NIH Criteria, served as a standard for researchers 
and clinicians for more than a decade. In 2003, a 
consensus workshop in Rotterdam in the Netherlands 
develo ped new diagnostic criteria, the Rotterdam 
Criteria. The Androgen Excess (AE) and PCOS 
Society proposed the AE-PCOS Criteria in 2006. It 
has an estimated prevalence o f  5-10% among adult 
females (2, 3). Limited data exists about incidence 
and prevalence of  PCOS in adolescent females and 
diagnosis continues to be challenging ( 4-6). Higher 
incidence o f  PCOS is seen with obesity, history of  
premature adrenarche, and family history o f  PCOS (7-
9). 
The exact etiology of  PCOS remains unknown, 
but there is evidence that supports genetic and 
lifestyle factors in the development of  PCOS. Studies 
have suggested the role of  insulin resistance for the 
development of  ovarian and pituitary dysfunction (I 0, 
11 ). In PCOS, there is relative increase in LH 
pulsatile secretion from the pituitary gland leading to 
altered high LH to FSH ratio (1.5-2:1). As a result, 
there is increase in ovarian androgen biosynthesis. In 
addition, high insulin levels stimulate ovarian 
androgen production and inhibit hepatic production o f  
sex hormone binding globulin. Further, decrease in 
pituitary FSH secretion leads to less aromatization of  
androgens to estradiol which affects follicular 
development and ovulation (12). 
In adolescent females, PCOS is often associated 
with obesity with increased risk of  metabolic 
disturbances, including impaired glucose tolerance 
and dyslipidemia. Treatment of  PCOS in adolescent 
female involves a multidisciplina r y  approach to 
decrease future risk of  endometrial cancer, diabetes 
mellitus and cardiovascular disease (13). It involves 
menstrual regulation, addressing features of  
hyperandrogenism such as hirsutism, acne, and 
weight management to improve insulin resistance. 
Treatment of  obesity has been associated with 
improvement in menstrual irregularity and insulin 
resistance (14). 
Menstrual regulation is often done using oral 
contraceptive pills, which also helps to improve sex 
hormone binding globulin and free testosterone. In 
addition, studies have found metforrnin to be 
beneficial for improving follicular develo pment and 
insulin resistance (14). Recent meta-analysis showed 
that lifestyle changes and metformin were associated 
with lower BMI and subcutaneous adipose tissue with 
improved menstruation in women with PCOS as 
compared with lifestyle changes only (15). 
Randomized control trials comparing metforrnin with 
oral contraceptive pills showed significant 
improvement in BMI over 6 month period (16, 17). 
Currently, there is limited data on long term changes 
in BMI in adolescent females with PCOS on 
treatment with metformin. In our study, it was 
hypothesized that adolescent female treated with 
metforrnin would have a decrease in BMI as 
compared to those on lifestyle modifications only 
when followed for at least a year. 
Methods 
A retrospective chart review of  adolescent females 
(12-21 years) who were seen, diagnosed and treated 
for PCOS in the Adolescent Medicine clinic was 
conducted. The study was approved by the 
Institutional Review Board. The charts were pulled 
using the billing diagnosis of  PCOS, obesity, and 
insulin resistance. Upon chart review, participants 
who met the NIH criteria of  PCOS ( oligo-ovulation, 
clinical or biochemical hy p er-androgenemia and 
exclusion of  other mimicking disorders) and followed 
up in clinic for at least one year on the same treatment 
plan (metforrnin only, metforrnin with oral 
contraceptives, oral contraceptives only, and lifestyle 
modifications only) were included. In order to be 
included in the study, charts needed to have the 
following data at an initial visit and follow up visit on 
the same treatment plan over at least a year: age, 
weight, and height. Charts with treatment plans such 
as Depo-Provera, implanon, intrauterine device, 
vaginal ring, and patch were excluded as they were 
not the focus o f  the present study. Using these criteria, 
134 out o f  464 charts reviewed were included in the 
study. Participants were then categorized into two 
groups based on treatment plan: metforrnin and 
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control. Participants who had been treated with 
metfomrin only or metfomrin and oral contraceptive 
pills were categorized as the metfomrin group. 
Participants who were treated with oral contraceptive 
pills only or lifestyle modifications without 
medication were included in control group. 
Nutritional counseling and lifestyle modification were 
part of  management in all participants. Participants 
were further classified as healthy (18.5-24.9), 
overweight (25-29.5), obese (2:30 kg/m2) and 
extremely obese (2:35 kg/m2) using CDC guidelines 
for Body Mass Index (BMI) in the treatment group. 
Descriptive analysis was done to identify those who 
increased, decreased or experienced no change in 
BM! from baseline to follow up. Chi-square analyses 
were performed to detemrine i f  groups differed in 
whether or not they increased, decreased, or stayed 
the same in terms ofBMI category. 
Results 
The average time period between initial visit and 
follow up on same treatment plan was 2 years 
(range = 1-8 years). The average age o f  patients at 
baseline was 15 .34 years and the average age at 
follow up was 17.7 years. While majority o f  patients 
were White (n = 82, 61.2%), others were identified as 
Black (n = 45, 33.6%), Hispanic (n = 3, 2.2%), Asian 
(n = 2, 1.5%), and two or more races (n = 2, 1.5%). 
About half o f  the patients were on metfomrin and oral 
contraceptive pills (n = 73, 54.5%). A third o f  patients 
(n = 44) were on oral contraceptive pills only. Only a 
few patients were on metfomrin only (n = 6, 4.5%). 
Eleven patients were not on any medication 
(n = 8.2% ). When grouped in two categories, 41 % 
(n = 55) patients were in the metfomrin group and 
59% (n = 79) in the control group. 
Table 1. Distribution of participants in Metformin and Control group and their BMI classification at baseline 
and follow up 
Study Group Healthy Weight Overweight Obese Extremely Obese 
Lifestyle modification Baseline 0(0%) 4 (36%) 6 (55%) I (9%) 
No metformin/ 
(n = 11), n (%) Follow-up I (9%) I (9%) 5 (46%) 4 (36%) Control group 
Birth Control Baseline 10 (23%) 15 (34%) 17 (39%) 2(4%) (n = 55) 
(n -44) ,  n (%) Follow-up II (25%) 7 (16%) 22 (50%) 4 (9%) 
Metformin + Birth Baseline 6(8%) 39 (53%) 10 (14%) 18 (25%) 
Metformin Control (n = 73), n (%) Follow-up 5 (7%) 5 (7%) 34 (46%) 29 (40%) 
group Metformin Baseline 0(0%) 0(0%) 5 (83%) I (17%) (n = 79) 
(n - 6 ) ,  n (%) Follow-up 0(0%) I (17%) 3 (50%) 2 (33%) 
Table 2. The percent o f  patients in each treatment group stayed in the same BMI classification or change 
BMI classifications 
No Change 
No Metformin (n = 55), n (%) 33 (60%) 
Metformin (n = 79), n (%) 56 (71%) 
At baseline and follow up, the majority o f  patients 
were overweight or obese (see Table I). No patients 
were underweight. The majority o f  patients 
experienced no change in BM! classification and few 
fell into a lower BMI classification at follow-up (see 
Table 2). There was not a siguificant difference 
between groups in the number o f  patients who stayed 
in the same BMI category, went up in a BM! 
category, or went down in a BMI category from 
baseline to follow-up (X2 = 1.93, p = 0.38). 
Increase Decrease 
17(31%) 5 (9%) 
19 (24%) 4(5%) 
Discussion 
Our study is among the first few to investigate 
changes in body mass index in adolescent females 
with PCOS on metformin versus not on metfomrin 
over an average duration o f  two years. In our study 
sample, adolescent females on metformin continued 
to be overweight or obese. This is in contrast to 
previous studies which had shown improvement in 
BM! when treated with metfomrin over a 6 month 
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period (16, 17). In those studies, the investigators 
ensured compliaoce aod adhereoce to a treatment 
regimeo through direct contact aod frequeot 
reminders. Adhereoce to treatmeot is ofteo a 
challeoge in adolesceoce. In our study sample, there 
was no significaot chaoge in BMI betweeo metformin 
aod control group. 1bis could be attributed to 
noncompliaoce to the treatmeot regimeo over a long 
period o f  time. Or, it could be that the initial weight 
loss observed in other studies is challeoged by 
lifestyle choices over the long term. Another 
limitation o f  the study is its retrospective nature. 
Giveo the retrospective nature o f  the data, there were 
several appointmeots where data was missing aod 
treatmeot plaos chaoged. Ideally, baseline aod follow 
up would be over the same amount o f  time for each 
patient. However, follow up appointments happened 
at different intervals aod sometimes did not have all 
the necessary data to allow for a comparison ( e.g., 
height was ofteo missing). Thus, i f  a follow up 
occurred at a year aod data were missing, a later 
follow up appoint that included all data needed to be 
selected. Some patients did not return for follow up 
appoints until over a year later. Furthermore, some 
patients' treatment plaos chaoged too frequently to 
allow for a baseline aod follow up comparison. 
Prospective studies could be designed to study effect 
o f  metformin on weight loss over a longer, consistent
period with emphasis on adherence.
References 
[!] Ehrmann DA. Polycystic ovary syodrome. N Engl J 
Med 2005;352(12):1223-36. 
[2] Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer 
ES, Yildiz BO. The prevalence and features of the 
polycystic ovary syndrome in an unselected population. 
J Clin Endocrinol Metab 2004;89(6):2745-9. 
[3] March WA, Moore VM, Willson KJ, Phillips DI, 
Nonnan RJ, Davies MJ. The prevalence of polycystic 
ovary syndrome in a community sample assessed under 
contrasting diagnostic criteria Hum Reprod 
2010;25(2):544-51. 
[4] Christensen SB, Black MH, Smith N, Martinez MM, 
Jacobsen SJ, Porter AH, et al. Prevalence of polycystic 
ovary syndrome in adolescents. Fertil Steril 
2013;100(2):470-7. 
[5] Diamanti-Kandaralris E. PCOS in adolescents. Best 
Pract Res Clin Obstet Gynaecol 2010;24: 173--1!3. 
[6] Hashemipour M, Faghihimani S, Zolfaghary B, 
Hovsepian S, Ahmadi F, Haghighi S. Prevalence of
polycystic ovary syndrome in girls aged 14--18 years in 
Isfahan, Iran. Honn Res 2004;62(6):278--1!2. 
[7] Alvarez-Blasco F, Botella-Carretero n, San Millan JL,
Escobar-Morreale HF. Prevalence and characteristics of
the polycystic ovary syndrome in overweight and obese 
women. Arch Intern Med 2006; 166:2081-<i. 
[8] Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz 
R. Prevalence of polycystic ovary syndrome (PCOS) in 
first-degree relatives of patients with PCOS. Fertil Steril 
2001;75:53-8. 
[9] Rosen.field RL. Clinical review: identifying children at 
risk for polycystic ovary syndrome. J Clin Endocrinol 
Metab 2007;92:787-96. 
[10] Dorne, MouilletJF, YanX, Ou Q, SadovskyY. Insulin 
enhances the transcription of luteinizing hormone-beta 
gene. Am J Obstet Gynecol 2004;191(1):132-7. 
[11] Stepto NK, Cassar S, Joham AE, Hutchison SK, 
Harrison CL, Goldstein RF, Teede HJ. Women with 
polycystic ovary syodrome have intrinsic insulin 
resistance on euglycaemic-hy p erinsulaemic cla m p. Hum 
Reprod 2013;28:777-84. 
[12] Goodsrzi MO, Dumesic DA, Chazenbalk G. Polycystic 
ovary syndrome: etiology, pathogenesis and diagnosis. 
Nat 2011;7:219--31. 
[13] Nicandri KF, Hoeger K. Diagnosis and treatment of
polycystic ovarian syndrome in adolescents. Curr Opin 
Endocrinol Diabetes Obes. 2012 Dec; 19(6):497-504. 
[14] Bugg, C ,  Rosen.field, R,L Polycystic ovary syndrome in 
adolescence. Endocrinol Metab Clin North Am 34 
(2005) 677-705. 
[15] Curi DDG, Fonseca AM, Marcondes JAM, Almeida 
JAM, Bagnoli VR, Soares Jr JM,Baracat EC. Metfonnin 
versus lifestyle changes in treating women with 
polycystic ovary syndrome. Gynecol Endocrinol 
2012;28:182-5. 
[16] Al-Zubeidi H, Klein KO. Randomized clinical trial 
evaluating metformin versus oral contraceptive pills in 
the treatment of adolescents with polycystic ovarian 
syndrome. J Pediatr Endocrinol Metab 2015;28(7-
8):853-8. doi: 10.1515/jpern-2014-0283. 
[17] Allen HF, Mazzoni C, Heptulla RA, Murray MA, Miller 
N, Koenigs L, et al. Randomized controlled trial 
evaluating response to metfonnin versus standard 
therapy in the treatment of adolescents with polycystic 
ovary syodrome. J Pediatr Endocrinol Metab 2005; 
18(8):761--1!. 
Submitted: August 05, 2015. Revised: Septetnber 15, 
2015. Accepted: September 27, 2015. 
